PNN

Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited ( BSE - FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26.

Key Financial Highlights

Q2 FY26 Standalone Financial Highlights

- Total Income of ₹ 145.29 Cr, YoY growth of 35.34%

- EBITDA of ₹ 22.34 Cr, YoY growth of 60.09%

- EBITDA Margin (%) of 15.37%, YoY growth of 238 Bps

- Net Profit of ₹ 9.73 Cr, YoY growth of 127.75%

- Net Profit Margin (%) of 6.70%, YoY growth of 272 Bps

- EPS of ₹ 20.61, YoY growth of 127.73%

H1 FY26 Standalone Financial Highlights

- Total Income of ₹ 265.15 Cr,

See Full Page